slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 63,721-63,750
Pages 2,605
Rows per page 30
Component
63,721-63,750 of 78,138
11
Uses a stacked bar chart to visualize the 'out of the money' status of contingent bonus obligations relative to growth rates.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
12
The chart illustrates the bridge from Gross Proceeds to Realised transaction proceeds, compared against the Fair Value.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
21
The chart shows a positive correlation between two variables (likely catalogue size/revenue and valuation multiple).Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
16
The 2023 figure is marked with an asterisk indicating revenue guidance.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
17
The chart shows a progression from negative margin to positive margin.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a bar chart to demonstrate financial discipline and outlines three key areas of investment.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
06
The slide uses a visual comparison to highlight the safety advantage of NXC-201, specifically focusing on neurotoxicity and CRS duration.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
10
The slide uses a comparative timeline/chart layout to contrast clinical outcomes of three different therapies.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Aha Moment1 hit
11
The chart demonstrates the efficacy of NXC-201 (formerly HBI0101) in clearing diseased cells.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
13
Includes extensive source citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
14
The slide uses a table structure to contrast treatment outcomes and patient growth across three stages of multiple myeloma.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
21
Combines market sizing data with a 'Why Now' narrative supported by industry news clippings and a comparative efficacy table.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
22
The slide uses a wave-like visual to represent market segments and their associated valuations.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
25
The chart uses a grouped bar structure to compare efficacy across patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
28
The chart illustrates deepening responses over time in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
41
The slide uses a scatter plot to map clinical trial outcomes (mPFS vs. prior lines of therapy) and a table to detail standard-of-care performance across lines of therapy.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
42
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a late-stage patient population.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
57
The slide uses a bar chart to compare two groups of oncology drugs, highlighting a significant revenue disparity.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
58
The slide uses a bar chart comparison to benchmark existing market leaders against placebo outcomes.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
07
The slide uses a mix of brand logos and a bar chart to illustrate portfolio composition and financial scale.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early Struggles1 hit
08
Uses a before-after framework to illustrate strategic evolution.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
09
The slide uses a split-screen layout comparing Kering Eyewear (historical growth chart) and Kering Beauté (timeline of recent developments).Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising SuccessLoop · Before After1 hit
15
The slide uses a donut chart to show the 77%/23% split between Retail and Wholesale, with further regional and sub-channel breakdowns.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
18
Waterfall chart illustrates revenue bridge between H1 22 and H1 23.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
21
Waterfall chart shows revenue bridge from H1 22 to H1 23.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
24
The chart uses a waterfall bridge to explain revenue variance between H1 2022 and H1 2023.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · The BreakthroughLoop · Maturity Curve1 hit
27
Waterfall chart illustrates revenue bridge from H1 2022 to H1 2023.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
30
The waterfall chart shows the bridge from H1 2022 to H1 2023 revenue for Kering Eyewear.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
33
The chart uses a waterfall bridge format to reconcile the opening and closing net debt positions.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit